I am here in vigorous opposition to SF 2841 that would implement mental health screening for three-year-old children entering public school. Continue reading →
David Graham, MD, FDA’s Associate Director of Science and Medicine who, throughout his career, has been a thorn for FDA managers by identifying hazardous drug effects. In 1999, his data helped identify the risk of liver damage from Pfizer’s diabetes drug Rezulin . . . Continue reading →
"I’m as big a fan of the 1st Amendment as anyone, but this decision strikes me as fundamentally flawed. We’re not talking about a right to express yourself. We’re talking about selling stuff — stuff that could harm or even kill you if used improperly." David Lazarus, LA Times Continue reading →
An audit by Daniel Levinson, Inspector General of DHHS, confirms what has already been documented: that antipsychotics are widely misprescribed for unapproved uses and taxpayers are saddled with the high cost through Medicaid and Medicare. Continue reading →
New FDA antipsychotic Warnings: "The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding." Continue reading →
According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel . . . Continue reading →
"The vote is an enormous blow to Avandia and GlaxoSmithKline. The vast majority of panel members voted either to withdraw the drug or to allow continued sales only if strict controls are added" Continue reading →
Despite the fact that children may be at highest risk of antidepressant-induced suicide, GlaxoSmithKline is testing Paxil on 7 to 18 year old Japanese children. Continue reading →
The US government is initiating several radical medical experiments that will ensure widespread, increased use of mostly toxic drugs whose adverse effects trigger chronic, debilitating illnesses.
Corporate business ethics and investors’ interests have swept aside the humanitarian foundation of American medicine and most of related healthcare, and caring service professions.
Continue reading →